Can-Fite subsidiary OphthaliX provides an update on its programs

Can-Fite BioPharma (CANF) subsidiary OphthaliX provides an update on its product development efforts.

Glaucoma: CF101 Phase 2 clinical trial in Israel and Europe ongoing. Protocol will be amended and testing will proceed to the second cohort where patients will treated with 2 mg of CF101 or placebo. The company expects to announce full study data in mid-2015.

Dry Eye Syndrome: The firm terminates the development of CF101 for this indication due to the lack of correlation between patients' responses to CF101 and the over-expression of the drug target, the A3 adenosine receptor.

OphthaliX is currently exploring in-licensing opportunities that will complement its ophthalmic diseases pipeline.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs